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toms as depression is poorer among ethnic minorities than among whites. Patient and
physician education campaigns aimed at addressing the cultural stigma and percep-
tions of depression as well as available treatment options available may increase likeli-
hood of diagnosis and possibly lead to better outcomes.
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PREVALENCE OF DEPRESSION IN EUROPE: A COMPARISON OF
FIVE COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess the prevalence of depression among ﬁ ve large European
nations. METHODS: TNS Healthcare’s European Healthcare Panel of individuals in
France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level. The self-reported epidemiological data is representa-
tive of population gender and age (18–24, 25–34, 35–44, 45–54, 55–64, 65–69 yrs) 
strata in respective countries, ensured by sampling and intensive panel management.
The survey collected information on select health conditions (incl. depression; in the 
past 12-months), quality of life and health care-utilization. RESULTS: In the TNS
European Healthcare Panel, 8,665, 25,265, 19,887, 59,850 and 47,340 individuals 
completed survey in the Netherlands, Germany, Italy, France and UK respectively. 
Prevalence of Depression varied widely between these 5 nations, as follows: Nether-
lands: 9.4%, Germany: 14.6%, U.K: 14.8%, France: 17.8%, Germany: 18.8%.
Within each country, burden of Depression varied by age and gender; distribution 
among male (18–24, 25–34, 35–44, 45–54, 55–64, 65 yrs: % pts) was: the Nether-
lands: 5.1%, 6.0%, 7.0%, 7.6%, 7.3%, 5.1%; Germany: 10.9%, 9.9%, 11.2%, 
13.7%, 10.6%, 3.7%; Italy: 9.9%, 7.4%, 9.5%, 10.9%, 11.3%, 9.4%; France: 
13.7%, 12.8%, 14.4%, 14.6%, 10.9%, 6.2%; U.K: 11.8%, 12.2%, 15.8%, 18.7%,
14.0%, 7.0%; distribution among female (18–24, 25–34, 35–44, 45–54, 55–64, 65
yrs: % pts) was: the Netherlands: 5.7%, 14.4%, 13.4%, 13.3%, 10.9%, 13.8%;
Germany: 18.9%, 17.9%, 19.8%, 24.2%, 16.0%, 8.2%; Italy: 17.7%, 17.7%, 
21.1%, 24.7%, 21.3%, 12.2%; France: 25.4%, 23.4%, 23.0%, 23.7%, 19.5%, 
15.5%; UK: 24.9%, 24.8%, 26.6%, 26.2%, 19.1%, 12.8%. General Practitioners
were the primary point of diagnosis and source of treatment, even though this statistic
varied between the countries. CONCLUSIONS: Prevalence of depression appears to
be substantial in the studied European nations and peaked in the 35–55 age-group.
Females had substantially higher disease burden, amounting to as much as twice as 
their male counterparts in certain age groups.
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OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Question-
naire (PQ-LES-Q) is made up of 14 items that assess quality of life (QoL) aspects
(Total) and a 1-item overall assessment (Overall). This post-hoc analysis determined 
whether patient’s assessment in QoL correlated with improvement as determined by 
the clinical assessment (i.e. PANSS; CGI-S). METHODS: A total of 302 patients (aged 
13–17) with schizophrenia participated in a 6-week, multicenter, double-blind, ran-
domized trial. The primary measure was mean change from baseline in PANSS Total
score (LOCF). Secondary measures included CGI-S and the PQ-LES-Q Total and
Overall. Relationships between percentage of change from baseline in PQ-LES-Q. 
Total and percentage of change in PANSS and between change from baseline in PQ-
LES-Q Total and change from baseline in CGI-S score were tested by Pearson correla-
tion and trend analysis (Cochran-Mantel-Haenszel). RESULTS: Aripiprazole showed
signiﬁ cant improvements over placebo in PANSS, CGI-S, and PQ-LES-Q Overall
(week 6; p  0.05; LOCF). Strong correlation was found between all measures in 
the overall population, including PQ-LES-Q Total versus PANSS Total score and PQ-
LES-Q Overall versus CGI-S (r  0.33 and 0.29; p  0.01). Analysis by treatment 
arm showed strong correlation between change in PQ-LES-Q Total versus change in 
PANSS Total in all groups (r  0.44; p  0.011; LOCF). Correlation between change
in PQ-LES-Q Overall versus change in CGI-S was signiﬁ cant in the 10 mg/day group 
(r  0.33; p  0.001; LOCF), but not for the 30 mg/day and placebo groups (r 
0.084). Categories of CGI-S and PANSS Total improvement correlated with change
in PQ-LES-Q (p  0.001; LOCF). CONCLUSIONS: Improvements in patient-assessed 
QoL were signiﬁ cantly correlated with clinician reported outcomes in the overall
population and in individual treatment groups. Aripiprazole 10 mg/day and the com-
bined treatment group demonstrated a signiﬁ cant correlation between improvements 
in global QoL and global severity of illness.
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OBJECTIVES: To examine the controversial practice of off-label prescribing of atypi-
cal antipsychotic drugs and to review research evidence pertaining to the economics 
of their use, safety, efﬁ cacy and appropriateness of such prescribing. METHODS: A
comprehensive review of scientiﬁ c literature published between 2001–2009, covering
all empirical studies that examined off-label prescribing of atypical antipsychotics. 
Quantitative and qualitative analyses of published secondary data for off-label uses 
of three leading atypical anti-psychotics were conducted to gain insights into preva-
lence of off-label use, costs, and mortality associated with their use. RESULTS: Twenty 
experimental and observational studies qualiﬁ ed for inclusion. Most study participants
were institutionalized elderly, Caucasian men, with Alzheimer’s disease. The newer 
atypicals accounted for more than $11 billion in annual sales and represented 90% 
of the antipsychotic market in 2005. There was a ﬁ ve-fold increase in the prescription
of these drugs particularly in children in the last decade and a half. Risperidone was
the most prescribed drug off-label. EPS, gait disturbances and weight gain were the 
most commonly cited adverse events. Elderly patients with dementia-related psychosis 
treated with atypical antipsychotics were found to be at an increased risk of adverse
events and death. CONCLUSIONS: The research evidence available to determine the
true extent and consequences of off-label prescribing of atypical antipsychotics, while 
scarce and conﬂ icting, is mostly critical of their use in children and elderly with 
dementia. Scientiﬁ c support documenting the efﬁ cacy and appropriateness of these 
drugs for treating depression and behavioral disorders of dementia is currently incon-
clusive. The high cost of these drugs may arguably offset the advantages stemming 
from their perceived lower side-effect proﬁ le.
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OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Question-
naire (PQ-LES-Q) is made up of 14 items that assess aspects of quality of life (Total) 
and a 1-item overall assessment (Overall). Quality of Life measures yield information 
independent of symptom measures. This post-hoc analysis investigated correlation 
between patient’s QoL assessment and objective clinical assessment (YMRS, CGI-BP). 
METHODS: A total 296 children (age 10–17) with bipolar disorder participated in a 
4-week double-blind trial of aripiprazole (10 or 30 mg/day, ﬁ xed doses) vs. placebo 
(PBO). Completers entered a 26 week extension. Primary outcome was mean change 
on YMRS Total Score. Secondary measures included mean changes on CGI-BP
Overall, PQ-LES-Q Total (T) and the Overall item (O). RESULTS: YMRS Total and 
CGI-BP Overall improved vs. PBO with both doses of aripiprazole at week 4 and 
week 30 (p  0.05 and p  0.01 respectively, LOCF). Both aripiprazole arms improved 
on PQ-LES-Q(T) and (O); however they did not reach statistical signiﬁ cance. Observed 
Cases analysis (OC) demonstrated a correlation at week 4 and week 30 between % 
change in PQ-LES-Q(T) and % change in YMRS (r  0.18 and 0.29, respectively; 
p  0.03). When 4 week YMRS Total improvement was put into categories (20%; 
20–30%; 30–50%; 50% reduction), % change in mean PQ-LES-Q(T) was 1.7, 2.3, 
12.5, & 10.4 per category (trend analysis p  0.007; regression p  0.01; OC). At 30 
weeks % change in mean PQ-LES-Q(T) was 3.3, NA, 2.6, 16.6 (p  0.02; Linear
regression p  0.02; OC). When CGI-BP Overall was put into 4 categories ( 0; 1; 
2; a3 point change) at 4 weeks, % change in mean PQ-LES-Q(O) was 0.02, 0.15, 
0.27, 0.43 per category (trend analysis p  0.05; OC) and at 30 weeks, % change in
mean PQ-LES-Q(O) was 1, 0, 0.63, 0.64 (p  0.02; OC). CONCLUSIONS: In this
trial of pediatric patients with BP there was positive correlation between patient-
assessed QoL measures and clinician-based assessment.
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OBJECTIVES: Antipsychotic drugs are widely used and costly. Little is known 
about how this has varied based on clinical applications and levels of evidence. 
METHODS: We used the IMS Health National Disease and Therapeutic Index to 
describe typical and atypical antipsychotic use from 1994 through 2007. We linked
this nationally representative cross-sectional data from outpatient physician practices 
to levels of evidence and FDA approval status from the FDA and the Drugdex
drug compendium. We obtained promotional and prescription expenditures from
IMS Health Integrated Promotional Services and the National Prescription Audit.
RESULTS: Preliminary results suggest aggregate annual antipsychotic use increased 
262% from 8 million physician visits (1994) to 21 million (2006), then declined to
19 million (2007). The market share of typical antipsychotics decreased from 86%
to 8% over this time period. Large increases in antipsychotic use occurred among 
individuals 18–64 (234%) and 18 years of age (559%). Increases were more modest
among those 65 years of age or older (131%). Antipsychotic use for schizophrenia
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declined from 76% to 31% as a share of all uses from 1994 to 2007, while substantial 
increases in use occurred for bipolar affective disorder (5% to 39%) and depression 
(8% to 15%). The fraction of atypical antipsychotic use for indications with insufﬁ -
cient evidence of efﬁ cacy increased from 32% in 1994 to 58% in 2007, representing
26 million prescriptions and $7.3 billion dollars in expenditures in 2007. During 2007, 
primary care physicians accounted for 21% of visits where an antipsychotic was
used, as compared with psychiatrists (77%) or physicians from other specialties 
(2%). Antipsychotic use in settings of insufﬁ cient evidence was similar among primary
care physicians and psychiatrists. CONCLUSIONS: The scope and costs of this 
expansion, due to both clinical innovation and overuse, demonstrate the importance
of efforts to limit the clinical application of antipsychotics to settings of sufﬁ cient 
evidence.
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OBJECTIVES: To validate adult ADHD prevalence estimates in a US health care
claims database. METHODS: A commercial research database (MarketScan from 
Thomson Reuters; employer clients only) was used to estimate the annual prevalence 
of adult ADHD from 2002 to 2007. Patients (18–64 years) diagnosed with ADHD 
(ICD-9) on at least 2 occasions within 12 months were counted in each year they 
had a diagnostic/drug claim indicating ADHD. These prevalence rates were compared
with rates from a US epidemiological study which estimated adult ADHD prevalence 
using clinical interviews of respondents (18–44 years) from the 2005 National Comor-
bidity Survey replication (NCS-R; Kessler et al, 2006). RESULTS: In MarketScan
the prevalence of diagnosed and treated ADHD in US adults was 1.24 per 1000 
members in 2002, increasing annually to more than triple in 2007 (4.02 per 1000). 
The proportion of females: males with ADHD increased yearly. Prevalence per 1000
grew faster among 18–24 than 25–64 year olds. ADHD with hyperactivity was more
prevalent than ADHD without hyperactivity. In contrast, the NCS-R study reported
a higher ADHD prevalence (44 per 1000) in 2005 in the 18–44 group, with more 
males than females diagnosed with ADHD. Prevalence estimates from our study 
increased when correcting for differences between studies in age range (18–64 versus 
18–44 years; 4.59 per 1000) and number of diagnoses (2 vs 1; 5.03 per 1000). In the
NCS-R study, only 10.9% of individuals who were diagnosed received treatment.
Thus, the number of treated patients in the NCR-S study (4.796 per 1000) is close to 
the 4.02 per 1000 reported from the claims database. CONCLUSIONS: The estimated 
prevalence of adult ADHD in diagnosed and treated patients based on claims data is 
similar to that based on clinical interviews, validating the use of claims data to estimate 
prevalence.
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OBJECTIVES: To evaluate the risk of injury associated with attention-deﬁ cit hyper-
activity disorder (ADHD) using information from an employee database. METHODS:
Using the MarketScan Commercial Claims and Encounters Database from Thomson 
Reuters, patients aged 18 to 64 years and diagnosed with ADHD (N  31,752) were 
matched by similarity in demographics and data availability 3:1 to controls without 
ADHD (N  95,256) or 1:1 to controls diagnosed with depression (N  29,965). 
Patients with ADHD were also stratiﬁ ed into compliant (Medication Possession Ratio 
[MPR] q0.8; N  8654), partially compliant (0.3 a MPR  0.8; N  5233) and non-
compliant (MPR  0.3; N  4007) cohorts. Risk of injury was compared between
groups for January to December 2006. Multivariate analyses controlled for treatment
differences between groups that remained after matching. RESULTS: Injury rates were 
higher in the ADHD group than in the non-ADHD control group (21.6% vs 15.7%,
p  0.001) and depression group (21.4% vs. 20.5%, p  0.0085), and higher in the 
compliant group than in the partially compliant (22.8% vs 20.3, p  0.0004) and 
noncompliant (22.8% vs 17.8%, p  0.001) groups. In multivariate analyses, risk of 
injury was higher in the ADHD group than in the non-ADHD (1.3194 odds ratio 
[OR], p  0.01) and depression control groups (1.1263 OR, p  0.01) and higher in
compliant and partially compliant patients than in noncompliant patients (1.2633 and
1.664 OR, respectively, p  0.01). Comorbid depression, anxiety and substance abuse 
predicted a higher risk of injury in the ADHD versus control groups (p  0.01) and 
in compliant/partially compliant patients versus noncompliant patients (p  0.01), with 
magnitude equal to or exceeding that of the ADHD group alone. CONCLUSIONS:
Patients with ADHD had higher risk of injury than similarly matched patients without 
ADHD or with depression, suggesting important implications for workplace safety
and liability.
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OBJECTIVES: Toxicovigilance studies were carried out with the aim to determine the
health hazards, treatment and outcome of therapeutic drug overdose. METHODS: All 
therapeutic drug poisoned patients admitted to a tertiary care South Indian hospital. 
were evaluated for predisposing factors manner of exposure, severity at admission,
treatment, hospitalization period, clinical status at discharge, , in order to implement 
medication safety programs. RESULTS: A total of 200 patients were admitted with 
therapeutic drug overdose. A total of 153 cases intentionally ingested the drugs, while 
29 cases had overdose during routine therapy, and 18 cases had ingested the drugs 
accidentally. Depression was the major predisposing factor for intentional self harm. 
Most of the poisoning with therapeutic drugs occurred due to intentional self harm n 
 153 (76.5%). Other manner of exposures include overdose during therapeutic use
n  29 (14.5%) or accidental exposure n  18 (9%). There was a signiﬁ cant (P 
0.001) association of employment and occupational status on the manner of exposure. 
The mean GCS, APACHE II scores, PMR and PSS for all the patients was 8.46 o 3.6; 
20.63 o 5.0; 38.58 o 16.1 and 2.96 o 0.79 (Mean o SD) respectively. The mean GCS 
score was signiﬁ cantly (P  0.033) different between various class of poisoning. The
APACHE II scores were not signiﬁ cantly (P  0.05) different between various drug 
classes. The mean severity scores was signiﬁ cantly (P  0.016) different between 
various class of drugs. The treatment provided was empirical and symptomatic with 
differing decontamination procedures. The average hospitalization period was 6.68 o
4.9 days with a median of 6 days range (3–8). Majority of them 189(94.5%) improved,
while 5 patients were discharged with severe sequele, and six patients expired during 
hospital stay. CONCLUSIONS: The extent of harm caused due to therapeutic drug 
poisoning can be minimized by systematically estimating the severity at triage and
providing treatment as per standardized guidelines.
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OBJECTIVES: The purpose of this study was to evaluate the relative efﬁ cacy and
safety of pregabalin and clonazepam in the treatment of anxiety disorders. METHODS:
A meta-analysis was performed with randomized clinical trials (RCTs) where pregaba-
lin or clonazepam were used for any anxiety disorders. Effectiveness was assessed with
the Hamilton Anxiety Rating Scale (HAM-A); safety with the frequency and type of 
adverse events (AEs). RCT were searched in July 2008 in Medline, EMBASE, PsycInfo, 
CINAHL and the Cochrane Collaboration. Two independent reviewers identiﬁ ed the 
abstracts, full articles, and then extracted data; results were compared and settled 
through consensus. RCT included both drugs and its comparison with placebo. Odds 
ratios and weighted means differences (WMD) were calculated. Both, ﬁ xed and 
random effects models were employed in the analysis. RESULTS: From 1893 abstracts, 
we obtained 40 RCT, 23 were excluded (unacceptable designs, insufﬁ cient outcome 
data, no placebo control) leaving 17. Seven pregabalin studies were used to evaluate 
its effectiveness and safety; four clonazepam studies for effectiveness and six for safety.
Clonazepam studies included panic disorder and social phobia. Six of seven pregabalin
studies were in generalized anxiety disorder and one for social anxiety disorder. We 
found that both drugs signiﬁ cantly diminished anxiety levels after four to 32 weeks 
of treatment. Among clonazepam studies the frequency of AEs was higher than
placebo by nearly 50%; with pregabalin, less than 30%. We didn’t found any head-
to-head studies with pregabalin and clonazepam and no statistical difference in anxiety 
level reduction was distinguished between drugs, WMD in HAM-A: 1.2(CI95% 1.13, 
3.54). However, clonazepam showed higher AE rates than pregabalin in somnolence 
(OR 0.54; 95%CI 0.44–0.66), headache (OR 0.50; 0.34–0.74), blurred vision (OR 
0.36; 0.13–0.98) and cognitive impairment (OR 0.25; 0.09–0.72). CONCLUSIONS:
Clonazepam and pregabalin are effective in diminishing anxiety levels in several
anxiety disorders, although clonazepam seems to cause a higher frequency of AEs.
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OBJECTIVES: Purpose of this analysis was to quantify the subgroup of schizophrenia
patients with potential treatment beneﬁ ts associated with the oral atypical antipsy-
chotic Paliperidone ER (PER) according to its clinical proﬁ le (limited liability for 
hepatic drug-drug interactions (DDI) via CYP450) and to assess the budgetary impact
of targeted use of PER for treatment of these patients. METHODS: In a retrospective 
study of longitudinal patient data from Germany using IMS Disease Analyzer, medical
records from patients with at least one diagnosis of schizophrenia (ICD10 F20-F29) 
between July 2007 and June 2008 were analyzed. For the last quarter of the study 
period prescriptions of antipsychotic and concomitant medication of schizophrenia 
